Leqembi - direct healthcare professional communication (DHPC)

Lecanemab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Lecanemab, Leqembi 100 mg/mL concentrate for solution for infusion – Update to magnetic resonance imaging (MRI) schedule to include an MRI scan prior to the third infusion of Leqembi

Key facts

• Medicine name:
  Leqembi
• Active substance:
  Lecanemab
• Therapeutic area (MeSH):
  • Cognitive Dysfunction
  • Alzheimer Disease
• Procedure number:
  EMA/VR/0000290573
• Regulatory outcome:
  Variation
• DHPC type:
  Post-authorisation measure
• Human ATC codes:
  N06DX04
• Dissemination date:
  26/09/2025